These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32692462)

  • 1. Abnormal laboratory findings and plasma concentration monitoring of lopinavir and ritonavir in COVID-19.
    Batteux B; Bodeau S; Gras-Champel V; Liabeuf S; Lanoix JP; Schmit JL; Andréjak C; Zerbib Y; Haye G; Masmoudi K; Lemaire-Hurtel AS; Bennis Y
    Br J Clin Pharmacol; 2021 Mar; 87(3):1547-1553. PubMed ID: 32692462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients.
    Chouchana L; Boujaafar S; Gana I; Preta LH; Regard L; Legendre P; Azoulay C; Canouï E; Zerbit J; Carlier N; Terrier B; Kernéis S; Batista R; Treluyer JM; Zheng Y; Benaboud S
    Ther Drug Monit; 2021 Feb; 43(1):131-135. PubMed ID: 33230045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.
    Dai L; Liu A; Zhang H; Wu H; Zhang T; Su B; Shao Y; Li J; Ye J; Scott SR; Mahajan SD; Schwartz SA; Yu H; Sun L
    Curr HIV Res; 2019; 17(5):324-334. PubMed ID: 31654514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
    Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.
    Decloedt EH; Maartens G; Smith P; Merry C; Bango F; McIlleron H
    PLoS One; 2012; 7(3):e32173. PubMed ID: 22412856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness concerns of lopinavir/ritonavir in COVID-19 affected patients: a retrospective series.
    Lepage MA; Rozza N; Kremer R; Grunbaum A
    Clin Toxicol (Phila); 2021 Jul; 59(7):644-647. PubMed ID: 33641562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens.
    Gutiérrez F; Padilla S; Navarro A; Masiá M; Hernández I; Ramos J; Esteban A; Martin-Hidalgo A
    J Acquir Immune Defic Syndr; 2003 Aug; 33(5):594-600. PubMed ID: 12902803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment.
    Macías J; Pinilla A; Lao-Dominguez FA; Corma A; Contreras-Macias E; González-Serna A; Gutierrez-Pizarraya A; Fernández-Fuertes M; Morillo-Verdugo R; Trigo M; Real LM; Pineda JA
    Sci Rep; 2020 Dec; 10(1):20958. PubMed ID: 33262433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19.
    Mohsenian Naghani S; Jansen MM; Jaspers T; Bastiaans D; Burger D
    Eur J Hosp Pharm; 2023 Mar; 30(e1):e106-e108. PubMed ID: 33990390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations.
    Gutiérrez F; Padilla S; Masiá M; Navarro A; Gallego J; Hernández I; Ramos JM; Martin-Hidalgo A
    Antivir Ther; 2004 Feb; 9(1):105-13. PubMed ID: 15040542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of early treatment of lopinavir-ritonavir in patients with severe COVID-19: a case series.
    Luo P; Zheng JL; Liu Y; Qiu L; Liu XL; Xue HY; Liu D; Li J
    Clin Med (Lond); 2021 Jan; 21(1):e80-e83. PubMed ID: 33355217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir.
    Brandariz-Nuñez D; Correas-Sanahuja M; Guarc E; Picón R; García B; Gil R
    Med Clin (Barc); 2020 Oct; 155(7):281-287. PubMed ID: 32718719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.
    Liu X; Ma Q; Zhao Y; Mu W; Sun X; Cheng Y; Zhang H; Ma Y; Zhang F
    Pharmacotherapy; 2017 Sep; 37(9):1073-1080. PubMed ID: 28718515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.
    Murphy RA; Marconi VC; Gandhi RT; Kuritzkes DR; Sunpath H
    PLoS One; 2012; 7(9):e44793. PubMed ID: 23028623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.
    Joseph BA; Dibas M; Evanson KW; Paranjape G; Vegivinti CTR; Selvan PT; Saravu K; Gupta N; Pulakurthi YS; Keesari PR; Varsha S; Chittajallu S; Dmytriw AA; Reierson NL; Mikoff N; Kamrowski S; Schmidt M; Davis AR; Pederson JM; Mishra HK; Touchette JC; Kallmes K
    Expert Rev Anti Infect Ther; 2021 Jun; 19(6):679-687. PubMed ID: 33187459
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients.
    Ramautarsing RA; van der Lugt J; Gorowara M; Sophonphan J; Ananworanich J; Lange JM; Burger DM; Phanuphak P; Ruxthungtham K; Avihingsanon A
    Antivir Ther; 2013; 18(2):249-52. PubMed ID: 22908131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration.
    Bierman WF; van Vonderen MG; Veldkamp AI; Burger DM; Danner SA; Reiss P; van Agtmael MA
    Antivir Ther; 2011; 16(5):647-55. PubMed ID: 21817186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patients.
    Lopez-Cortes LF; Ruiz-Valderas R; Sánchez-Rivas E; Lluch A; Gutierrez-Valencia A; Torres-Cornejo A; Benmarzouk-Hidalgo OJ; Viciana P
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3746-51. PubMed ID: 23716055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.